Harbour Antibodies

Harbour Antibodies BV was established in 2006 to use transgenic mouse technology developed in the laboratory of Professor Frank Grosveld at Erasmus MC (Rotterdam, the Netherlands) for engineering mice to produce high affinity human antibodies. The company has developed two types of human immunoglobulin gene transgenic mice: mice that generate “conventional” tetrameric antibodies comprising two heavy and two light immunoglobulin chains (H2L2); and alternatively, mice that generate heavy chain only antibodies comprising two immunoglobulin heavy chains with no light chains (HCAbs). Availability of HCAbs facilitates the generation of soluble human VH domains (human heavy chain variable region domains), the minimal immunoglobulin recognition unit, and thus the construction of novel multi-functional molecules comprising either two (or more) VH domains or one VH domain coupled to other molecules. Both Harbour transgenic mouse lines are now available to licensing partners.
Company Growth (employees)
Type
Private
HQ
Cambridge, US
Founded
2006
Size (employees)
3 (est)-25%
Harbour Antibodies was founded in 2006 and is headquartered in Cambridge, US

Key People at Harbour Antibodies

Robert Kamen

Robert Kamen

Director
Frank Grosveld

Frank Grosveld

CSO and Founder

Harbour Antibodies Office Locations

Harbour Antibodies has an office in Cambridge

Harbour Antibodies Data and Metrics

Summary Metrics

Founding Date

2006

Total Funding

$3.2 m

Latest funding size

$3.2 m

Time since last funding

about 4 years

Investors

Harbour Antibodies's latest funding round in July 2013 was reported to be $3.2 m. In total, Harbour Antibodies has raised $3.2 m

Traffic Overview of Harbour Antibodies

Harbour Antibodies Company Life and Culture

You may also be interested in